ABSTRACT HMG-CoA reductase catalyzes the conversion of hydroxymethylglutarate to mevalonate, an important early rate-limiting step in the cholesterol biosynthesis pathway. Since the discovery of compactin, the first HMG-CoA reductase inhibitor, by Endo et al. in 534-538, 1987. THE ROLE OF hypercholesterolemia, or more accurately hyperbetalipoproteinemia, as a risk factor for atherosclerosis in general and ischemic heart disease in particular is supported by a wealth of clinical, epidemiologic, and pathologic studies. A National Institutes of Health Consensus Development Panel recently concluded' that the ideal blood cholesterol for all Americans over the age of 30 is 200 mg/dl or less, and that attempts should be made to lower blood cholesterol when it exceeds the 75th percentile, or approximately 240 mg/dl, in middle-aged American men. Therapy should always start with a lipid-lowering diet, but diets acceptable to most patients typically lower blood cholesterol by 10% or less. Drug therapy has been limited by insufficient efficacy at tolerated doses, and in some cases a high instance of side effects and/or significant safety problems.2
THE ROLE OF hypercholesterolemia, or more accurately hyperbetalipoproteinemia, as a risk factor for atherosclerosis in general and ischemic heart disease in particular is supported by a wealth of clinical, epidemiologic, and pathologic studies. A National Institutes of Health Consensus Development Panel recently concluded' that the ideal blood cholesterol for all Americans over the age of 30 is 200 mg/dl or less, and that attempts should be made to lower blood cholesterol when it exceeds the 75th percentile, or approximately 240 mg/dl, in middle-aged American men. Therapy should always start with a lipid-lowering diet, but diets acceptable to most patients typically lower blood cholesterol by 10% or less. Drug therapy has been limited by insufficient efficacy at tolerated doses, and in some cases a high instance of side effects and/or significant safety problems. 2 In individuals eating a typical Western diet, approximately one-third of total body cholesterol is derived from the diet, and two-thirds is synthesized, mainly by the liver and intestine. The biosynthetic pathway for cholesterol involves more than 25 different enzymes, and is summarized in figure 1. An important ratelimiting step in this pathway is the conversion of hydroxymethylglutaryl-coenzyme A (HMG-CoA) to mevalonate, which is catalyzed by HMG-CoA reductase. Early attempts to inhibit cholesterol synthesis were centered on the late stages of the pathway. One such inhibitor, triparanol (MER/29), was used briefly in the clinic, but was withdrawn in 1962 after reports of serious toxicity, including cataracts, ichthyosis, and alopecia. Triparanol inhibited the conversion of desmosterol to cholesterol, and consequently caused the buildup of desmosterol in plasma and tissues. 17 the indication is that lovastatin reduces the concentration of circulating LDL particles. Consistent with the effects on HDL cholesterol, the concentrations of apo Al and apo All (which are carried in HDL) also tend to rise slightly."' 14 The time course of the therapeutic response is shown in figure 3 . The maximum therapeutic response is obtained in 4 to 6 weeks, after which the response is quite stable. The effects of progressive increases in dose on plasma cholesterol are shown in figure 4 . Lovastatin is given with meals, in single or divided doses. Divided doses are slightly more effective,14, 18 but single daily doses are more convenient and may be adequate for patients with milder forms of hypercholesterolemia. If the drug is given once a day, a dose given in the evening is more effective than the same dose given in the morning,18 probably because human cholesterol synthesis reaches a peak around midnight. ' It is clear that the mechanism of action of lovastatin is not simply and solely due to inhibition of cholesterol synthesis. In five patients studied by sterol balance techniques, Grundy and Bilheimer23 showed a modest decline in fecal output of neutral and acidic sterols in three patients but no changes in another two. Changes in the fecal output of sterols did not correlate with the degree of lowering of LDL cholesterol. Bilheimer et al. 9 had earlier shown that lovastatin could increase the fractional catabolic rate of LDL in patients with FH, which may indicate an increase in the number of LDL receptors. The importance of the LDL receptor is supported by limited data in patients with homozygous FH, who have very few or no functioning LDL receptors, and in whom lovastatin is relatively ineffective.'2 In one patient with homozygous FH in whom functioning LDL receptors were restored by means of liver transplantation, lovastatin reduced LDL cholesterol by 41%.24Grundy and Vega13 studied a group of patients with nonfamilial hypercholesterolemia in whom they were unable to establish a convincing effect on LDL catabolism, but did find decreases in LDL production rate. They interpreted these data to indicate that induction of the LDL receptor also occurred in these patients, but was manifested primarily by increased catabolism of VLDL remnants, rather than of LDL. Since LDL is formed from VLDL remnants, LDL production rate could be lowered by this mechanism. It is clear that lovastatin causes substantial reductions in VLDL cholesterol, 10, 14 whose measurement by ultracentrifugation includes VLDL remnants, but whether this is due to an increase in remnant catabolism or a decrease in VLDL secretion, or both, has not been established.
In summary, the mechanism of action of lovastatin is complex and not yet fully understood. It seems probable that different mechanisms may predominate in different patients, and there may well be differences between patients with and without FH. The technical difficulties of performing these studies are formidable. Therefore, an early resolution of the problem is not expected. Tolerability and safety. Lovastatin has been given to more than 1000 patients for up to 4 years. As of September 1986, about 500 patients had taken the drug for more than 1 year. I have reviewed all available data on all patients who have been treated with lovastatin. In controlled clinical studies, involving about 750 patients, the frequency ofpatient withdrawal from therapy due to adverse events attributable to lovastatin was less than 1%, indicating that lovastatin is a very welltolerated drug. Various 1.9% of patients have had larger and persistent asymptomatic increases of transaminases, particularly SGPT, which has been observed to rise above three times the upper limit of normal. When the drug was discontinued, the transaminases returned to pretreatment levels, usually within a few weeks. In contrast to the small increases in transaminases that appear early in therapy, the larger increases have usually occurred after at least 3 months on drug. Alkaline phosphatase remained essentially normal, indicating that the effect is most probably hepatocellular rather than cholestatic. It is clear that these idiosyncratic increases in transaminases are not the result of hypersensitivity, but otherwise the mechanism of the effect is unknown. In dogs, lovastatin produces posterior and anterior subcapsular cataracts in about 10% of treated animals, albeit at doses at least 50 times the maximum therapeutic dose. This phenomenon was not noted in rats or mice. * Because of this finding and the recorded effects of triparanol,4 the ophthalmologic data on patients treated with lovastatin have been scrutinized very carefully. More than 600 patients have had full ophthalmologic examinations, including slit-lamp biomicroscopy of the lens, at baseline and once or more during treatment.
Lens opacities were reported at baseline in approximately 30% of patients, which was not unexpected in view of the fact that lens opacities are very common in middle age.26 In controlled studies, the prevalence of lens opacities remained essentially unchanged during treatment with lovastatin. In one early study in 101 patients,14 an increase in the prevalence of lens opacities was reported; however, this experience is atypical and is probably the result of bias induced by the finding of cataracts in dogs, which were discovered after almost all patients in this study had had their baseline examinations, but before the majority had had their posttreatment examination. (It is well known that the detection of small lens opacities is subjective and depends, for example, on the time the examiner spends and the degree of pupillary dilatation achieved.) Thus 
